Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

atters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX2931 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... results that exceed the top end of its guidance ... of 2015 increased 10 percent to $79.5 million, compared ... of 2014. The Company,s revenue guidance range for the ... increase was driven by outperformance in the System One ...
(Date:5/6/2015)... 6, 2015  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... today that it will host a conference call and ... for the period ended March 31, 2015 and to ... its clinical program for aramchol. Conference ...
(Date:5/6/2015)...   Sigma-Aldrich Corporation (NASDAQ: SIAL ) a ... a $50,000 product donation to the Reproducibility Project: ... findings from recent high-impact papers in the field of ... online research marketplace Science Exchange , the non-profit ... journal eLife. The goal of the project ...
Breaking Medicine Technology:NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 2NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 3NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 4NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 5NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 6NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 7NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 8NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 9NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 10NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 11Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015 2Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015 3Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3
... Reportlinker.com announces that a new ... its catalogue: Neurostimulation ... Landscape and Market Forecasts to 2017 ... Neurostimulation Devices - Global ...
... 2011 Reportlinker.com announces that a new market ... South and Central America Drug Delivery ... http://www.reportlinker.com/p0548442/South-and-Central-America-Drug-Delivery-Devices-Market-Outlook-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory South and Central ... Summary GlobalData,s ...
Cached Medicine Technology:Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Reportlinker Adds South and Central America Drug Delivery Devices Market Outlook to 2017 2
(Date:5/6/2015)... (PRWEB) May 06, 2015 Dr. Vito C. ... plastic surgeons , recently completed a medical mission trip to ... on those affected by microtia and other deformities of ... April 17 and ended on April 26, Dr. Quatela and ... Microtia is a congenital deformity where the outside of the ...
(Date:5/6/2015)... The GUARDaHEART Foundation was proud to ... with the mission of providing basic living essentials and ... on Thursday, April 30th. , Through its partnership ... for the early-detection and diagnosis of heart disease, GUARDaHEART ... testing to homeless individuals and families. , “Heart ...
(Date:5/6/2015)... Mesa, Arizona (PRWEB) May 6, ... Ventures, Inc. (MAV), an investor backed Colorado cannabis ... based Phoenician Engineering subsidiary three times since first ... achieved profitability from operations, within one year of ... the end of 2014 to over 500 today ...
(Date:5/6/2015)... The American Water Resources Association (AWRA) ... prestigious Integrated Water Resources Management (IWRM) award , recognizing ... resources projects. , An IWRM approach to water resources has ... In 2014, 12 projects were nominated for the award. The ... only the 2014 AWRA IWRM Award winner - One Water, ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Doctors who ... reported what they are calling “unprecedented” tumor control in ... on the new research. Click here to read ... pembrolizumab to 25 mesothelioma patients between March and December ... in April. , “Pembrolizumab… provides robust antitumor activity in ...
Breaking Medicine News(10 mins):Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 2Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 3Health News:GUARDaHEART and Starbucks® Collaborate for Impactful Event to Help Homeless Families 2Health News:Cannibus Industry Start-Up Reaches Profitability While Expanding Its Proprietary Ancillary Medical Marijuana Product IP Portfolio 2Health News:Nominations Sought for Integrated Water Resources Management (IWRM) Award 2Health News:Researchers Say “Unprecedented” Mesothelioma Response Possible with Skin Cancer Drug, According to Surviving Mesothelioma 2
... tend to have fewer playmates than their non-aggressive ... comparison, non-aggressive children do better at interactions with ... findings of new research that used an important ... researchers at Arizona State University and published in ...
... emphasize physical symptoms of depression (e.g. headaches, poor appetite ... the few available empirical studies report mixed data on ... for Addiction and Mental Health (CAMH) debunks this cultural ... context when assessing a patient, leading to more accurate ...
... Mich. A new vision screening device, already shown to ... and patients a head start on treating diabetes and its ... invented by two scientists at the University of Michigan Kellogg ... stress and tissue damage that occur before the first symptoms ...
... and Inspiration to Local Heart Surgeon, PHOENIX, July ... Michael E. DeBakey, M.D. who died this past weekend ... who,performed the world,s first coronary artery bypass surgery, was ... and medical director of the,Arizona Heart Institute and Arizona ...
... many,people who have called and asked how they could help, ... with Tony Snow,s children,s education and,expenses., Jill Snow, Tony,s ... Kendall, Robbie and Kristi, as beneficiaries. Donations can,be made directly ... check,made payable to the "Tony Snow Family Trust" to:, ...
... delivers nationwide distribution for IgeaCare,s telephony-based, nurse ... AZ, July 14 /PRNewswire/ - IgeaCare Systems USA, ... a distribution agreement with Jenne,Distributors, Inc. to offer ... authorized dealers nationwide. IgeaCare provides a,telephony-based e-call and ...
Cached Medicine News:Health News:Aggressive preschoolers found to have fewer friends than others 2Health News:Culture and depression 2Health News:'Snapshots' of eyes could serve as early warning of diabetes 2Health News:'Snapshots' of eyes could serve as early warning of diabetes 3Health News:Arizona Heart Institute Remembers Heart Surgery Pioneer Dr. Michael E. DeBakey 2Health News:IgeaCare Systems USA, Inc. enters distribution agreement with Jenne Distributors, Inc. 2Health News:IgeaCare Systems USA, Inc. enters distribution agreement with Jenne Distributors, Inc. 3
... refrigerator is specially designed ... blood in standard 500ml ... Standard AS3864 1997. Quiet ... utilising CFC Free refrigerant ...
TBR-720-2-GD is large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standard AS38...
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... circulating testosterone exists as unbound or free ... to SHBG with high affinity [1], while ... Both the albumin-bound and free fractions may ... testosterone action. Measurement of the free or ...
Medicine Products: